News from mallinckrodt plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

06:45 ET Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the...

Feb 12, 2021, 06:45 ET Mallinckrodt Provides Regulatory Update on StrataGraft®

Mallinckrodt plc, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that...

Jan 29, 2021, 15:16 ET Mallinckrodt Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index

Mallinckrodt plc, a global biopharmaceutical company, today announced that it received a score of 100 on the Human Rights Campaign Foundation's 2021...

Nov 16, 2020, 06:45 ET Mallinckrodt Announces Real World Data on Hepatorenal Syndrome (HRS) and Acute Kidney Injury (AKI) in Patients with Liver Disease at The Liver Meeting Digital Experience

Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review of patient profiles and outcomes of...

Nov 16, 2020, 06:30 ET Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience

Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of a retrospective chart review study of...

Nov 10, 2020, 06:47 ET Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients

Mallinckrodt plc, a global biopharmaceutical company, today announced initiation of a retrospective chart review study, titled "Nitric Oxide...

Oct 29, 2020, 06:35 ET Mallinckrodt Announces Data at Kidney Week 2020 Reimagined that Showed A Potential for Reduced Need for Renal Replacement (RRT) Therapy for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Treated with Terlipressin

Mallinckrodt plc, a global biopharmaceutical company, today announced results from two post-hoc studies of its investigational agent terlipressin in...

Oct 14, 2020, 20:23 ET Mallinckrodt Receives Court Approval of "First Day" Motions to Support Business Operations

Mallinckrodt plc ("Mallinckrodt" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of...

Oct 12, 2020, 00:12 ET Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring

Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that it has voluntarily initiated Chapter 11 proceedings in the U.S....

Aug 10, 2020, 06:46 ET Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for...

Aug 04, 2020, 06:00 ET Mallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline Advancements

Second quarter net sales of $166.5 million net of the retrospective one-time Acthar® Gel Medicaid liability; adjusted net sales of $700.9 million, a...

Jul 15, 2020, 18:12 ET Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U....

Jun 17, 2020, 06:45 ET Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success...

Jun 15, 2020, 10:50 ET Mallinckrodt to Proceed with Appeal Despite Appellate Court Decision Denying Temporary Injunction in Ongoing Acthar Gel Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced its disappointment with the U.S. Court of Appeals for the District of...

Jun 15, 2020, 06:30 ET Mallinckrodt to Present Phase 3 StrataGraft® Regenerative Skin Tissue Clinical Trial Results on Severe Burns During the Virtual American Burn Association 52nd Annual Meeting

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present data from the pivotal Phase 3 clinical trial...

Jun 09, 2020, 06:32 ET Mallinckrodt Completes Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has completed its rolling...

Jun 01, 2020, 06:45 ET Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will appeal a ruling by the U.S. District Court for the...

May 05, 2020, 06:45 ET Mallinckrodt plc Reports Earnings for the First Quarter 2020 and Highlights Pipeline Progress

First quarter net sales of $665.8 million, with diluted loss per share of $0.60, with results impacted in part by competitive and payer pressures in...

Apr 16, 2020, 06:45 ET Mallinckrodt to Report Earnings Results for First Quarter 2020

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report first quarter 2020 earnings results for the...

Apr 06, 2020, 06:45 ET Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has...

Mar 16, 2020, 06:00 ET Mallinckrodt Confirms Court Decision in Lawsuit Against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and Provides Update Related to Global Opioid Settlement and Present Financing Activities

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today confirmed that its subsidiary, Mallinckrodt ARD LLC, received a decision from ...

Mar 11, 2020, 06:00 ET Mallinckrodt Provides Update on Proposed Global Opioid Settlement

Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that New York State Attorney General Letitia James has joined 47 other ...

Feb 25, 2020, 06:05 ET Mallinckrodt plc Reports Strong Fourth Quarter and 2019 Results

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today reported results for the three months and fiscal year ended Dec. 27, 2019....

Feb 25, 2020, 06:00 ET Mallinckrodt Announces Agreement in Principle for Global Opioid Settlement and Associated Debt Refinancing Activities

Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that the Company and its specialty generics-focused subsidiaries...

Feb 14, 2020, 07:38 ET Mallinckrodt to Report Earnings Results for Fourth Quarter and Fiscal 2019

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report fourth quarter and fiscal 2019 earnings results ...